Skip to content
SitemapMIA Media2021-09-10T15:30:19+10:00
Pages
Posts by category
- Category: Forums
- Category: Awareness
- Category: Careers
- Category: Education
- Category: Events
- Category: Fundraising
- Category: Partners
- Category: Patient Support
- Category: People
- Category: Research News
- Category: Research Projects
- Category: Uncategorized
Papers
- Melanomas in children and adolescents: clinicopathologic features and survival outcomes.
- Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
- Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases.
- Incorporating carbon into health care: adding carbon emissions to health technology assessments.
- Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma.
- Reflectance confocal microscopy in Australia: Perspectives on barriers to implementation and uptake.
- Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.
- The effect of organ-specific tumor microenvironments on response patterns to immunotherapy.
- Informing a position statement on the use of artificial intelligence in dermatology in Australia.
- BRAF inhibitor cessation prior to disease progression in metastatic melanoma: long term outcomes.
- Toripalimab vs High-Dose Interferon-α2b as Adjuvant Therapy for Resected Mucosal Melanoma.
- Which strategies support the effective use of clinical practice guidelines and clinical quality registry data to inform health service delivery? A systematic review.
- Phase 1b Study of Cobimetinib Plus Atezolizumab in Patients with Advanced BRAFV600 Wild-Type Melanoma Progressing on Prior Anti–Programmed Death-1 Therapy.
- Dataset for the Reporting of Merkel Cell Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
- Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma.
- ASO Visual Abstract: Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma-An International Multi-institutional Collaboration.
- Tertiary lymphoid structures accompanied by fibrillary matrix morphology impact anti-tumor immunity in basal cell carcinomas.
- Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study.
- Discussion of costs and financial burden in clinical practice: A survey of medical oncologists in Australia.
- Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
- Clinical Management of Melanocytic Tumours of Uncertain Malignant Potential (MelTUMPs), including Melanocytomas: A Systematic Review and Meta-Analysis.
- Motivations and Barriers to Participation in a Randomized Trial on Melanoma Genomic Risk: A Mixed-Methods Analysis.
- Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
- Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.
- Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
- Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance.
- Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
- Metastasizing and non-metastasizing thick melanoma: clinicopathological predictors and molecular profiling.
- Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework.
- Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.
- Obesity is associated with altered tumor metabolism in metastatic melanoma.
- Hypoxia controls the glycome signature and galectin-8 - ligand axis to promote pro-tumorigenic properties of metastatic melanoma.
- Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
- Communicating Personal Melanoma Polygenic Risk Information: Participants’ Experiences of Genetic Counseling in a Community-Based Study.
- Validation of self-reported sun exposure against electronic ultraviolet radiation dosimeters.
- Recursive Partitioning to Determine Order of Significance of Regional Metastasis Characteristics in Head and Neck Cutaneous Squamous Cell Carcinoma.
- Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.
- Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
- Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE).
- Navigating the cellular landscape in tissue: Recent advances in defining the pathogenesis of human disease.
- Comparative genomics provides etiological and biological insights into melanoma subtypes
- Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.
- Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.
- In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response.
- Views of the Australian public on the delivery of risk-stratified cancer screening in the population: a qualitative study.
- Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting.
- Assessing the value of precision medicine health technologies to detect and manage melanoma.
- Utility of optical coherence tomography in basal cell naevus syndrome: A case report
- Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.
- Developing an Australian Melanoma Clinical Outcomes Registry (MelCOR): a protocol paper.
- Survival outcomes of perineural spread in head and neck cutaneous squamous cell carcinoma.
- KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.
- High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma
- Sentinel node biopsy: linchpin of melanoma management.
- Response to 'Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable.
- Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
- Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma.
- Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.
- Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck.
- Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations.
- Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.
- Protein-based classification of melanoma differentiation subtypes.
- Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
- MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
- Outcomes after definitive treatment for head and neck angiosarcoma.
- The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies.
- Changes in sun protection behaviours, sun exposure and shade availability among adults, children and adolescents in New South Wales, 2003-2016.
- Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.
- Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells.
- Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
- A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era.
- Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms.
- Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial.
- Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
- Adaptive designs for clinical trials have potential advantages, but statistical challenges lurk!
- Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma.
- KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
- Optical coherence tomography features of a tumour of the follicular infundibulum.
- Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside.
- Case report of a challenging medium-sized congenital melanocytic nevus (CMN): Highlighting a role for reflectance confocal microscopy (RCM) for evaluating changing CMN in children.
- Association Between Melanoma Detected During Routine Skin Checks and Mortality.
- Complex melanoma of the scalp: Diagnosis and management aided by confocal microscopy.
- Review BRAF inhibition and the spectrum of granulomatous reactions.
- Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006.
- Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.
- Acute bilateral phrenic nerve neuropathy causing hypercapnic respiratory associated with checkpoint inhibitor immunotherapy.
- Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis.
- High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
- Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
- Interventions to Increase Sunscreen Use in Adults: A Review of the Literature.
- Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
- Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
- Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas
- Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
- Irregular Sleep/Wake Patterns Are Associated With Reduced Quality of Life in Post-treatment Cancer Patients: A Study Across Three Cancer Cohorts
- A practical guide on the use of Imiquimod cream for Lentigo Maligna.
- Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
- Immune checkpoint inhibitors in melanoma
- Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.
- PARP Inhibitors in Melanoma-An Expanding Therapeutic Option?
- Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.
- Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition.
- Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas.
- Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis.
- Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma.
- Strengthening melanoma prevention and early detection among people with type 2 diabetes.
- A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era.
- TMB and Inflammatory Gene Expression Associated With Clinical Outcomes Following Immunotherapy in Advanced Melanoma
- Residual melanoma in wide local excision specimens after 'complete' excision of primary cutaneous in situ and invasive melanomas.
- Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial
- The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
- Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy
- Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma
- ASO Author Reflections: Surgical Resection May Improve the Outcome for Patients with Residual Metastatic Melanoma When Modern Systemic Therapies Have Not Achieved Complete Disease Control
- In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?
- Confocal microscopy, dermoscopy, and histopathology features of atypical intraepidermal melanocytic proliferations associated with evolution to melanoma in situ
- Correction to: Histological regression in melanoma: impact on sentinel lymph node status and survival.
- Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma
- Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply
- Surveillance of patients with thin melanoma.
- Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy.
- Deep Learning for Basal Cell Carcinoma Detection for Reflectance Confocal Microscopy.
- Histological regression in melanoma: impact on sentinel lymph node status and survival.
- Knowledge, views and expectations for cancer polygenic risk testing in clinical practice: a cross-sectional survey of health professionals.
- Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
- Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
- Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations.
- A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences.
- Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires Clear Diagnostic Criteria That Are Consistently Applied-Reply.
- Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets.
- Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy.
- Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location.
- Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers.
- Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma.
- Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies.
- Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
- PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.
- Identifying the 'Active Ingredients' of an Effective Psychological Intervention to Reduce Fear of Cancer Recurrence: A Process Evaluation.
- Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma.
- Neoadjuvant Immunotherapy in Melanoma – The New Frontier
- Neoadjuvant immunotherapy in melanoma - the new frontier
- Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi
- Counting mitoses: SI(ze) matters!
- Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis.
- Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity.
- Current Challenges in Access to Melanoma Care: A Multidisciplinary Perspective.
- Validation of the American Joint Committee on Cancer Staging in Squamous Cell Carcinoma of the Vermilion Lip
- Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience.
- Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data.
- Melanoma Cell State-Specific Responses to TNFα
- An independent external validation of melanoma risk prediction models using the Australian Melanoma Family Study.
- Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
- Talimogene laherparepvec monotherapy for head and neck melanoma patients.
Events
Portfolio
Academic Authors
- Martin, Linda
- Wilmott, James
- Mann, Graham
- van Akkooi, Alexander
- Menzies, Alex
- Morton, Rachael
- Nieweg, Omgo
- Pennington, Tom
- Long, Georgina
- Rawson, Robert
- Guitera, Pascale
- Rizos, Helen
- Carlino, Matteo
- Rtshiladze, Michael
- Ch'ng, Sydney
- Saw, Robyn
- Cust, Anne
- Scolyer, Richard
- Ferguson, Peter
- Shannon, Kerwin
- Hersey, Peter
- Spillane, Andrew
- Hong, Angela
- Stretch, Jonathan
- Thompson, John
- Lo, Serigne
- Varey, Alex
Page load link
